FDA

R&D

parental permission, child assent, and consent in clinical trials

Parental permission, child assent, and adolescent autonomy i...

As a vulnerable population, children in general must rely on their parents or guardians to provide informed consent for them to participate in research.

News

FDA competition seeks digital endpoints for Parkinson’s

The FDA is asking digital health technology developers to come up with a solution to measuring a common symptom of Parkinson’s disease that can have a serious impact on pa

News

FDA delays decision on Moderna’s RSV vaccine

Moderna’s first attempt to expand its commercial activities beyond COVID-19 vaccines, its respiratory syncytial virus (RSV) shot, has suffered a delay in the US.

News

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

The FDA has confirmed that it will convene an advisory committee meeting on 10th June to discuss Eli Lilly’s Alzheimer’s disease candidate donanemab, after announcing a de

News

Apple gets FDA okay to use AFib tool in clinical trials

The atrial fibrillation (AFib) detection feature on Apple Watch devices has become the first digital health technology to be qualified under a programme recently introduce

R&D

Partner Content

Final FDA rule on LDTs creates a paradigm shift for laborato...

WASHINGTON, D.C., April 30, 2024 –The Food and Drug Administration’s (FDA) final rule has reclassified laboratory developed tests (LDTs) as medical devices, according to Avalere.

Parental permission, child assent, and adolescent autonomy i...

FDA competition seeks digital endpoints for Parkinson’s

FDA delays decision on Moderna’s RSV vaccine

FDA sets June adcomm date for Lilly’s Alzheimer’s drug

Apple gets FDA okay to use AFib tool in clinical trials

Final FDA rule on LDTs creates a paradigm shift for laborato...

Europe is facing a surge in STIs, says ECDC

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks